Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
Jia Li, Muhammad Wasif SaifYale Cancer Center, Yale School of Medicine, New Haven CT, USAAbstract: Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced...
Saved in:
Main Authors: | Jia Li, Muhammad Wasif Saif |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2009
|
Subjects: | |
Online Access: | https://doaj.org/article/4d99a45cd9d247f0b2e0be29ea4bccc8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bevacizumab in the treatment of ovarian cancer
by: Ramez N Eskander, et al.
Published: (2011) -
Bevacizumab in the treatment of HER2-negative breast cancer
by: Vito Lorusso
Published: (2008) -
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
by: Richard Quek, et al.
Published: (2010) -
Bevacizumab in the therapy for refractory metastatic colorectal cancer
by: Mary F Mulcahy
Published: (2008) -
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
by: Bernard Escudier, et al.
Published: (2008)